Key result
Furosemide matches bumetanide in heart failure efficacy, offering easier titration but higher ototoxicity risk.
Why the study?
To compare furosemide and bumetanide to evaluate whether one drug has higher efficacy and under which circumstances one is preferable over the other.
Does furosemide or bumetanide have higher efficacy or preferable characteristics in treating congestive heart failure and edema?
Does furosemide or bumetanide have higher efficacy or preferable characteristics in treating congestive heart failure and edema?
Furosemide and bumetanide are equally effective for heart failure diuresis, but differ in bioavailability, titration ease, and ototoxicity risk.
Answers are grounded in this paper and cite their sources.
Loop diuretic review may inform agent choice by pharmacokinetics; leaves open need for outcome trials in HF and hypertension.
Loop diuretics are widely used in the treatment of hypertension and edema caused by cardiovascular, renal, and hepatic dysfunction. Furosemide and bumetanide are 2 of the more commonly prescribed loop diuretics. Sharing a common mechanism of action of blocking the Na+-K+-2Cl- cotransporter in the thick ascending loop of Henle, these drugs can be used to promote diuresis and electrolyte excretion. This article reviews the uses of these loop diuretics and compares and contrasts the pharmacology, efficacy in treating congestive heart failure, adverse effects, and clinical trials comparing the 2 drugs to evaluate whether one drug has higher efficacy and under which circumstances it is preferable to use one drug over another. Numerous studies have shown that furosemide and bumetanide are both equally effective in treating congestive heart failure and the peripheral edema associated with it. As they both possess side effects that can be caused by low electrolyte levels, it is important to monitor these values during administration. Furosemide possesses a lower relative dose ratio to bumetanide, allowing the dosage to be more easily titrated for individual requirements, while bumetanide has a lower risk of ototoxicity and has a higher bioavailability.
No takes yet. Share an insight, caveat, or question.
Dolan et al. (2026) conducted a review in Congestive heart failure and edema. Furosemide vs. Bumetanide was evaluated. Furosemide and bumetanide are equally effective in treating congestive heart failure and peripheral edema, though furosemide allows easier dose titration and bumetanide has lower ototoxicity risk.
Synapse has enriched 10 related papers. Consider them for comparative context: